Sinopharm Group Second Quarter 2024 Earnings: CN¥0.13 loss per share (vs CN¥0.19 loss in 2Q 2023)

Simply Wall St.08-28

Sinopharm Group (HKG:1099) Second Quarter 2024 ResultsKey Financial Results Net loss: CN¥419.6m (loss narrowed by 31% from 2Q 2023). CN¥0.13 loss per share (improved from CN¥0.19 loss in 2Q 2023). ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2462065891?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496","is_english":true,"pubTime":"2024-08-28 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2462065891","market":"hk","top_or_hot":-1,"title":"Sinopharm Group Second Quarter 2024 Earnings: CN¥0.13 loss per share (vs CN¥0.19 loss in 2Q 2023)","media":"Simply Wall St.","content":"<div>\n<p>Sinopharm Group (HKG:1099) Second Quarter 2024 ResultsKey Financial Results Net loss: CN¥419.6m (loss narrowed by 31% from 2Q 2023). CN¥0.13 loss per share (improved from CN¥0.19 loss in 2Q 2023).  ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-second-quarter-2024-earnings-cn013-loss-per\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Group Second Quarter 2024 Earnings: CN¥0.13 loss per share (vs CN¥0.19 loss in 2Q 2023)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Group Second Quarter 2024 Earnings: CN¥0.13 loss per share (vs CN¥0.19 loss in 2Q 2023)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-28 08:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-second-quarter-2024-earnings-cn013-loss-per><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sinopharm Group (HKG:1099) Second Quarter 2024 ResultsKey Financial Results Net loss: CN¥419.6m (loss narrowed by 31% from 2Q 2023). CN¥0.13 loss per share (improved from CN¥0.19 loss in 2Q 2023).  ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-second-quarter-2024-earnings-cn013-loss-per\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CN","symbol_name":"Xtrackers MSCI All China Equity ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-second-quarter-2024-earnings-cn013-loss-per","article_id":"2462065891","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2462065891","pubTimestamp":1724804369,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sinopharm Group ( HKG:1099 ) Second Quarter 2024 Results Key Financial Results Net loss: CN¥419.6m (loss narrowed by...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CN":"Xtrackers MSCI All China Equity ETF","01099":"国药控股"},"translate_title":"国药集团2024年第二季度收益：每股亏损0.13元人民币（2023年第二季度亏损0.19元人民币）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1,"CN":1},"content_text":"Sinopharm Group (HKG:1099) Second Quarter 2024 ResultsKey Financial Results Net loss: CN¥419.6m (loss narrowed by 31% from 2Q 2023). CN¥0.13 loss per share (improved from CN¥0.19 loss in 2Q 2023).  SEHK:1099 Earnings and Revenue Growth August 28th 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Sinopharm Group Earnings Insights  Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare industry in Hong Kong.    Performance of the Hong Kong Healthcare industry.  The company's shares are down 9.5% from a week ago.   Balance Sheet Analysis While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet.  We've done some analysis and you can see our take on Sinopharm Group's balance sheet. New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2462065891"}